Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.64
$0.491.19%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -118.86% | -69.85% | -60.90% | -46.87% | -349.06% |
| Total Depreciation and Amortization | 169.85% | 135.21% | 86.72% | 34.26% | 4.17% |
| Total Amortization of Deferred Charges | 24.60% | 52.38% | 151.82% | 509.09% | -- |
| Total Other Non-Cash Items | 25.82% | 5.99% | 4.44% | 5.30% | -15.81% |
| Change in Net Operating Assets | 132.18% | 420.12% | -90.39% | -112.40% | -169.31% |
| Cash from Operations | -139.63% | -77.08% | -206.59% | -21,863.28% | -1,408.16% |
| Capital Expenditure | -196.84% | -149.46% | -99.12% | -19.76% | 13.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 198.60% | 165.16% | -- | -- | -- |
| Cash from Investing | 197.22% | 161.60% | -10,071.09% | -23,182.17% | -24,580.72% |
| Total Debt Issued | -50.00% | -50.00% | -75.00% | -75.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.08% | 34.17% | -98.95% | 24,518.36% | 23,070.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 93.63% | -213.53% |
| Cash from Financing | 38.50% | 18.19% | -93.98% | 317.60% | 447,457.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 253.79% | 499.55% | -301.94% | -679.52% | -3,231.39% |